Alkermes Inc

Type: Company
Name: Alkermes Inc
Nationality: United States
Web Address: http://www.alkermes.com/
Fact Sheet: Fact Sheet for Alkermes Inc
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Alkermes (ALKS) Trading Near $46.70 Resistance Level

Jul 25, 2014 (Marketintelligencecenter.com via COMTEX News Network) -- Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Alkermes Inc ( ALKS ) that should provide a 11.08% return in just 120 days. ... [Published PredictWallStreet - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

Alkermes plc To Host Conference Call To Discuss Second Quarter 2014 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, July 31, 2014, to discuss the company’s financial results for the second quarter of 2014. Management will review the quarter and provide an update on ... [Published BioSpace - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Alkermes receives Notices of Allowance for US patents for four CNS pipeline candidates

Alkermes has announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of its pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ALKS 3831 ... [Published Manufacturing Chemist - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

10 Job Openings in Waltham

Accountant at Stephen James in Waltham. at NAPA in Waltham. at Community Health Network in Waltham. at Altria Group Distribution Co. in Waltham.Recruitment Administrator at KNF&T Staffing Resources in Waltham.Commercial Counsel at Alkermes in Waltham. ... [Published Waltham Patch - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Eli Lilly EPS Estimates Improved In Past Month

Analysts have become increasingly bullish on Eli Lilly in the month leading up to the company’s second-quarter earnings announcement scheduled for Thursday, July 24, 2014. The consensus earnings per share estimate has moved up from 64 cents a share to ... [Published Forbes.com - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis

By a News Reporter-Staff News Editor at Health & Medicine Week -- Alkermes plc (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis ... [Published 4 Traders - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Who's Next Pharma on the Tax Inversion Bullseye?

According to Bloomberg, that list would include Perrigo Co., in Ireland and Actelion Ltd, in Switzerland. Both would offer US acquirers the chance to redomicile to friendlier tax environs and cut their corporate rates by up to 1/3. It's all the rage you ... [Published The Big Red Biotech Blog - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Alkermes

plc – A Global Biopharmaceutical CompanyAlkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.Our CompanyLatest NewsYou ... [Published Bioresearch Online - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Alkermes Starts Phase I Study Of Potential MS Treatment

By Lori ClapperDublin drug manufacturer Alkermes has initiated a phase I clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule intended for the treatment of multiple sclerosis (MS). The launch of this trial could hopefully lead to some ... [Published Bioresearch Online - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Alkermes Kicks Off Its Phase 1 Clinical Study of ALKS 8700

Alkermes has initiated the phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). According to a release from the company, the randomized, double-blind study will evaluate ... [Published Individual.com - Jul 22 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 8 reports

Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). ... [Published PBR - News - Jul 18 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 7 reports

Alkermes gets notices of allowance for US patents for four CNS pipeline candidates

Alkermes has announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes’ pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ... [Published PBR - News - Jul 10 2014]

Quotes

...and determine the therapeutic utility and differentiating features of ALKS 8700," said Dr Elliot Ehrich, Chief Medical Officer of Alkermes. "ALKS 8700 leverages Alkermes' expertise in prodrug chemistry and oral controlled-release formulations to offer potential differentiated tolerability and dosing for patients with MS."
...CNS medicines and reflect the significant innovations our scientific teams are making,' said Dr Elliot Ehrich, Chief Medical Officer of Alkermes. "Aripiprazole lauroxil, ALKS 5461, ALKS 3831 and ALKS 7106 each represent novel therapeutic approaches with potential to address unmet needs in their respective disease areas."
...founded, 4D Biomedical, with the emphasis being on encouraging collaboration between the National Health Service (NHS), universities and industry. "It's about making sure that Britain is unlocking and using all of our assets through the NHS, through medical research" Freeman told BBC Radio Norfolk this week...

More Content

All (245) | News (105) | Reports (0) | Blogs (129) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Alkermes (ALKS) Trading Near $46.33 Resistance ... [Published MarketIntelligenceCenter.com - 15 hours ago]
Alkermes (ALKS) Trading Near $46.70 Resistance ... [Published PredictWallStreet - Jul 25 2014]
Alkermes plc To Host Conference Call To Discuss... [Published BioSpace - Jul 25 2014]
Alkermes initiates Phase I multiple sclerosis s... [Published Individual.com - Jul 25 2014]
Alkermes (ALKS) Trading Near $46.70 Resistance ... [Published MarketIntelligenceCenter.com - Jul 25 2014]
Acorda Fighting Six Generic Challenges to Ampyra [Published FDA News - Jul 25 2014]
Alkermes to Host Conference Call to Discuss Sec... [Published Myrtle Beach Sun News - Jul 24 2014]
Alkermes to Host Conference Call to Discuss Sec... [Published Business Wire Health News - Jul 24 2014]
The Zacks Analyst Blog Highlights: AbbVie, Shir... [Published Yahoo! Finance - Jul 24 2014]
Alkermes (ALKS) Showing Support Near $44.99 [Published MarketIntelligenceCenter.com - Jul 24 2014]
Alkermes receives Notices of Allowance for US p... [Published Manufacturing Chemist - Jul 24 2014]
10 Job Openings in Waltham [Published Waltham Patch - Jul 24 2014]
Eli Lilly EPS Estimates Improved In Past Month [Published Forbes.com - Jul 24 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published 4 Traders - Jul 23 2014]
Biotech Stock Roundup: AbbVie's Tax Inversion, ... [Published Nasdaq - Jul 23 2014]
Potential Alkermes (ALKS) Trade Has 8.15% Downs... [Published MarketIntelligenceCenter.com - Jul 23 2014]
Who's Next Pharma on the Tax Inversion Bullseye? [Published The Big Red Biotech Blog - Jul 22 2014]
'Volunteers' Fighting Marijuana Legalization in... [Published High Times - Jul 22 2014]
Jay-Z and Scarface: pharma staff’s anonymous Wi... [Published In-Pharmatechnologist - Jul 22 2014]
Alkermes Starts Phase I Study Of Potential MS T... [Published Bioresearch Online - Jul 22 2014]
Alkermes [Published Bioresearch Online - Jul 22 2014]
Alkermes (ALKS) Trading Near $46.69 Resistance ... [Published MarketIntelligenceCenter.com - Jul 22 2014]
Despite The Sell-Off, Zohydro Is A Falling Knif... [Published Seeking Alpha - Jul 22 2014]
Alkermes Kicks Off Its Phase 1 Clinical Study o... [Published Individual.com - Jul 22 2014]
Alkermes' Pipeline Development Impresses, Key U... [Published Zacks.com - Jul 21 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Jul 21 2014]
Patent Office Reports Notices of Allowance for ... [Published HighBeam Research - Jul 19 2014]
Can Anything Stop Drug Companies From Fleeing T... [Published Forbes.com - Jul 19 2014]
Patent Office Reports Notices of Allowance for ... [Published 4 Traders - Jul 19 2014]
Alkermes begins Phase 1 clinical study of ALKS ... [Published Individual.com - Jul 18 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alkermes (ALKS) Trading Near $46.33 Resistance ... [Published MarketIntelligenceCenter.com - 15 hours ago]
The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with Alkermes Inc (ALKS) that should provide a 11.27% return in just 117 days. Sell one Nov. '14 call at the $46.00 level for ...
Alkermes (ALKS) Trading Near $46.70 Resistance ... [Published MarketIntelligenceCenter.com - Jul 25 2014]
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Alkermes Inc (ALKS) that should provide a 11.08% return in just 120 days. Sell one Nov. '14 call at the $47.00 level for each 100 shares of Alkermes ...
Alkermes to Host Conference Call to Discuss Sec... [Published Business Wire Health News - Jul 24 2014]
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, July 31, 2014, to discuss the company’s financial results for the second quarter of 2014. Management will review the quarter ...
Alkermes (ALKS) Showing Support Near $44.99 [Published MarketIntelligenceCenter.com - Jul 24 2014]
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Alkermes Inc (ALKS). Look at the Nov. '14 $47.00 covered call for a net debit in the $42.51 area. This trade has a duration of 121 days. ...
Potential Alkermes (ALKS) Trade Has 8.15% Downs... [Published MarketIntelligenceCenter.com - Jul 23 2014]
After closing Tuesday at $45.42, Alkermes Inc (ALKS) presents an attractive opportunity to get a 10.26% return in just 122 days, which is an annualized return of 30.69% (for comparison purposes only). To enter this trade, sell one Nov. '14 $46.00 call ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Clinical Trial Data, NDA Submissions, and Board... [Published Financial Services - Jun 25 2014]
Biotech Equities Under Review -- Research on Ac... [Published Financial Services - May 09 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Certifications, Authorizations, Stock Updates, ... [Published Financial Services - Apr 10 2014]
Health Care Stocks Technical Coverage -- Resear... [Published Financial Services - Apr 09 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.